Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome

Diabetology & Metabolic Syndrome

Elena Kirienkova²  Igor Vaysbeyn¹  Pavel Zatolokin³  Nikolai Fattakhov²  Mariia Vasilenko²  Dmitriy Atochin⁴  Larisa Litvinova² 

[1] Department of General Surgery, Kaliningrad Regional Hospital, Building 74, Klinicheskaya St., Kaliningrad, Russia;Innovation Park, Immanuel Kant Baltic Federal University, Building 3, Botkina St., Kaliningrad, Russia;Department of Reconstructive and Endoscopic Surgery, Kaliningrad Regional Hospital, Building 74, Klinicheskaya St., Kaliningrad, Russia;Cardiovascular Research Center, Massachusetts General Hospital, 149 East, 13th street, Charlestown, MA 02129, USA

关键词: Gene expression;    Adipokine;    Obesity;    Inflammation;    Adipose tissue;    Metabolic syndrome;   

Others  :  1128716
DOI  :  10.1186/1758-5996-6-137

 received in 2014-09-15, accepted in 2014-12-02,  发布年份 2014

【 摘 要 】

Background

The purpose of this research was to study the gene expression of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), nuclear factor kappa B (NF-κB), vascular endothelial growth factor A (VEGF-A) and adiponectin (AdipoQ) genes in the visceral (omental, mesenteric) and subcutaneous adipose tissue depots in metabolic syndrome (MS).

We studied 23 women with MS, with a mean age of 50.7 ± 4.5 years and mean body mass index (BMI) of 45.6 ± 9.8 kg/m². The control group included 10 women, with a mean age of 40.6 ± 8.7 years and normal BMI (22.3 ± 3.7 kg/m²). The gene expression levels in the omental (OAT), mesenteric (MAT) and subcutaneous (SAT) adipose tissues were assessed by quantitative real-time PCR.

Findings

Increased gene expression levels of IL-6 and TNF-α were detected in MAT in patients with MS, compared with the control group (p < 0.05 and p < 0.005, respectively). Significant positive correlations were observed between IL-6 mRNA expression levels in OAT and the content of CD14 + cells in the peripheral blood (r = 0.55, p < 0.05), as well as between NF-κB and VEGF-A mRNA levels in OAT (r = 0.43, p < 0.05) in patients with MS. The AdipoQ gene expression levels in OAT were significantly decreased in women with MS compared with the control group (p < 0.05). In addition, there were inverse correlations between AdipoQ gene levels in MAT and serum CRP levels (r = −0.63, p < 0.05), as well as between AdipoQ gene levels in MAT and serum IL-6 levels (r = −0.46, p < 0.05).

Conclusion

These data demonstrate that proinflammatory gene expression of MAT in women with MS was increased compared with the control group. The AdipoQ gene expression levels in OAT were significantly decreased in women with MS compared with the control group.

【 授权许可】

   
2014 Litvinova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Paoletti R, Bolego C, Poli A, Cignarella A: Metabolic syndrome, inflammation and atherosclerosis. J Vasc Health Risk Manag 2006, 2(2):145-152.
• [2]Mirmiran PA, Noori N, Azizi F: Prospective study of determinants of the metabolic syndrome in adults. Nutr Metab Cardiovasc Dis 2008, 18:567-573.
• [3]Alberti KG, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. J Diabet Med 2006, 5:469-480.
• [4]Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Näslund E, Britton T, Concha H, Hassan M, Rydén M, Frisén J, Arner P: Dynamics of fat cell turnover in humans. Nature 2008, 453:783-787.
• [5]Litvinova LS, Kirienkova EV, Gazatova ND, Zatolokin PA, Vasilenko MA, Simbirtsev AS, Aksenova NN: Features of the cytokine-producing ability of peripheral blood mononuclear cells in the metabolic syndrome. Cytokines Inflamm 2013, 12:56-60.
• [6]Kulikov DI, Vasilenko MA, Kirienkova EV, Mazunin IO, Zatolokin PA, Litvinova LS: Research of a role of cellular and serum components and peripheral blood white adipose tissue in the formation chronic inflammatory and metabolic obesity. Bulletin BFU. Immanuel Kant 2013, 4:51-56.
• [7]Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11(2):85-97. doi:10.1038/nri2921
• [8]Lyon CJ, Law RE, Hsueh WA: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144:2195-2200.
• [9]Lehr S, Hartwig S, Sell H: Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 2012, 6:91-101.
• [10]Hirabara SM, Gorjão R, Vinolo MA, Rodrigues AC, Nachbar RT, Curi R: Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol 2012, 379024. doi:10.1155/2012/379024
• [11]Mathis D: Immunological goings-on in visceral adipose tissue. Cell Metab 2013, 17(6):851-859.
• [12]Litvinova LS, Kirienkova EV, Mazunin IO, Vasilenko MA, Fattakhov NS: Pathogenesis of insulin resistance in metabolic obesity. Biochem (Moscow) Suppl Ser B: Biomed Chem 2014, 8(3):192-202.
• [13]Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
• [14]Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005, 115(5):911-919.
• [15]Kirienkova EV, Litvinova LS, Seledtzov VI, Zatolokin PA, Aksenova NN: Effect of surgical correction of obesity (gastric bypass) for the metabolic syndrome in the biochemical parameters of blood. Klin Lab Diag 2012, 12:3-5.
• [16]Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004, 15(11):2792-2800.
• [17]Fain JN: Release of Inflammatory Mediators by Human Adipose Tissue Is Enhanced in Obesity and Primarily by the Nonfat Cells: A Review. J Mediators of Inflammation 2010, 513948. doi:10.1155/2010/513948
• [18]Dusserre E, Moulin P, Vidal H: Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000, 1500:88-96.
• [19]Jensen MD: Adipose tissue and fatty acid metabolism in humans. J R Soc Med 2002, 95(42):3-7.
• [20]Geer EB, Shen W: Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009, 6(Suppl 1):60-75.
• [21]Després JP, Nadeau A, Tremblay A, Ferland M, Moorjani S, Lupien PJ, Thériault G, Pinault S, Bouchard C: Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989, 38(3):304-309.
• [22]Kuk JL, Lee S, Heymsfield SB, Ross R: Waist circumference and abdominal adipose tissue distribution: influence of age and sex. Am J Clin Nutr 2005, 81(6):1330-1334.
• [23]Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome--a new worldwide definition. Lancet 2005, 366(9491):1059-1062.
• [24]Pfaffl MW: A new mathematical model for relative quantification in real time RT–PCR. Nucleic Acids Res 2001, 1:29-45.
• [25]Coppack SW: Pro–inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001, 60:349-356.
• [26]Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord: J Int Assoc Study Obes 2003, 27(Suppl 3):53-55. doi:10.1038/sj.ijo.0802502
• [27]Tronko ND, Kovzun UM, Pushkarev VM: Reception and intracellular mechanisms of insulin action (literature review). NAMS Ukraine 2012, 4:430-439.
• [28]Hocking S, Samocha-Bonet D, Milner KL, Greenfield JR, Chisholm DJ: Adiposity and insulin resistance in humans: the role of the different tissue and cellular lipid depots. Endocr Rev 2013, 34:239-277.
• [29]Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis study (IRAS). Circulation 2000, 102:42-47.
• [30]Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
• [31]Fernandez-Real JM: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rew 2003, 24:278-301.
• [32]Winkler G, Kiss S, Keszthelyi L, Sapi Z, Ory I, Salamon F, Kovacs M, Vargha P, Szekeres O, Speer G, Karadi I, Sikter M, Kaszas E, Dworak O, Karoly GG: Expression of tumor necrosis factor (TNF)-a protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-a, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol 2003, 149:129-135.
• [33]Elewaut D, DiDonato JA, Kim JM, Truong F, Eckmann L, Kagnoff MF: NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol 1999, 163:1457-1466.
• [34]Basak S, Hoffmann A: Crosstalk via the NF-κB signaling system. Cytokine Growth Factor Rev 2008, 19:187-197.
• [35]Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN: The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 2009, 106:13505-13510.
• [36]Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L: IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. J FASEB 2003, 17:2115-2117.
• [37]Roy H, Bhardwaj S, Ylä-Herttuala S: Biology of vascular endothelial growth factors. FEBS Lett 2006, 580:2879-2887.
• [38]Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
• [39]Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K: Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002, 105:373-379.
• [40]Silha JV, Krsek M, Sucharda P, Murphy LJ: Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005, 29:1308-1314.
• [41]Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y: Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003, 46(11):1483-1488.
• [42]Hagberg CE, Mehlem A, Falkevall A, Muhl L, Fam BC, Ortsäter H, Scotney P, Nyqvist D, Samén E, Lu L, Stone-Elander S, Proietto J, Andrikopoulos S, Sjöholm A, Nash A, Eriksson U: Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012, 18:426-430.
• [43]Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE: Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009, 58:718-725.
• [44]Diez JJ, Iglesias P: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocr 2003, 148:293-300.
• [45]Coughlin CC, Finck BN, Eagon JC, Halpin J, Magkos F, Mohammed BS: Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity 2007, 15:640-645.
• [46]Behre CJ, Gummesson AJ, Lystig TC: Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese subjects with and without the metabolic syndrome. Metabolism 2007, 56:1022-1028.
• [47]Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
• [48]Moreno-Navarrete JM, Ortega F, Gómez-Serrano M, García-Santos E, Ricart W, Tinahones F, Mingrone G, Peral B, Fernández-Real JM: The MRC1/CD68 ratio is positively associated with adipose tissue lipogenesis and with muscle mitochondrial gene expression in humans. PLoS One 2013, 8(8):e70810. doi:10.1371/journal.pone.0070810
• [49]Kranendonk ME, de Kleijn DP, Kalkhoven E, Kanhai DA, Uiterwaal CS, van der Graaf Y, Pasterkamp G, Visseren FL, SMART Study Group: Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. Cardiovasc Diabetol 2014, 13:37. doi: 10.1186/1475-2840-13-37 BioMed Central Full Text
• [50]Vinagre I, Sánchez-Quesada JL, Sánchez-Hernández J, Santos D, Ordoñez-Llanos J, De Leiva A, Pérez A: Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc Diabetol 2014, 13:34. doi: 10.1186/1475-2840-13-34 BioMed Central Full Text
• [51]Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
• [52]Calle MC, Fernandez ML: Inflammation and type 2 diabetes. Diab Metab 2012, 38:183-191.
• [53]Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y, Ouchi N, Kihara S, Funahashi T: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
• [54]Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I: CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 2008, 129(5):815-822.
• [55]Devaraj S, Torok N, Dasu MR, Samols D, Jialal I: Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adiposetissue-vascular loop. Arterioscler Thromb Vasc Biol 2008, 28(7):1368-1374.
• [56]Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F: Evidence for a link between adipose tissue interleukin-6 content and serum C reactive protein concentrations in obese subjects. Circulation 1999, 99:2221-2222.
• [57]Rebuffe-Scrive M, Anderson B, Olbe L, Bjorntorp P: Metabolism of adipose tissue in intra-abdominal depots of non-obese men and women. Metabolism 1989, 38:453-458.
• [58]Liu KH, Chan YL, Chan JCN, Chan WB: Association of carotid intima-media thickness with mesenteric, preperitoneal and subcutaneous fat thickness. Atherosclerosis 2005, 179:299-304.
• [59]Liu KH, Chan YL, Chan WB, Chan JC, Chu CW: Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness. Diabetes Care 2006, 29(2):379-384.